Study: NCT00550550

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo sublingual tablet, once daily

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCH 697243
Description: Grass sublingual tablet, once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Loratadine Syrup 1 mg/mL Rescue Treatment
Description: Loratadine Syrup 1 mg/mL was dosed orally once daily at a dose of 5 mg for children aged 5 to \<6 years of age and at a dose of 10 mg for children aged 6 to \<18 years of age as rescue medication for symptoms of rhinoconjunctivitis among participants with a total symptom score ≥4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loratadine Syrup 1 mg/mL Rescue Treatment
Description: Loratadine Syrup 1 mg/mL was dosed orally once daily at a dose of 5 mg for children aged 5 to \<6 years of age and at a dose of 10 mg for children aged 6 to \<18 years of age as rescue medication for symptoms of rhinoconjunctivitis among participants with a total symptom score ≥4.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Loratadine 10 mg Rescue Treatment
Description: Loratadine 10 mg RediTabs tablets were dosed orally once daily at a dose of 10 mg for children aged 6 to \<18 years of age as rescue medication for symptoms of rhinoconjunctivitis among participants with a total symptom score ≥4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loratadine 10 mg Rescue Treatment
Description: Loratadine 10 mg RediTabs tablets were dosed orally once daily at a dose of 10 mg for children aged 6 to \<18 years of age as rescue medication for symptoms of rhinoconjunctivitis among participants with a total symptom score ≥4.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Olopatadine 0.1% Rescue Treatment
Description: Olopatadine hydrochloride 0.1% ophthalmic solution was dosed intraocularly at a dose of 1 drop in each affected eye twice daily, in addition to loratadine, as rescue medication for participants with persistent eye symptoms due to rhinoconjunctivitis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olopatadine 0.1% Rescue Treatment
Description: Olopatadine hydrochloride 0.1% ophthalmic solution was dosed intraocularly at a dose of 1 drop in each affected eye twice daily, in addition to loratadine, as rescue medication for participants with persistent eye symptoms due to rhinoconjunctivitis.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mometasone furoate 50 mcg Rescue Treatment
Description: Mometasone furoate monohydrate nasal spray 50 mcg was dosed intranasally at a dose of one spray in each nostril once daily for participants aged 5 to \<12 years and a dose of 2 sprays in each nostril once daily for participants aged 12 to \<18 years as rescue medication for nasal symptoms of rhinoconjunctivitis among participants with a total symptom score of ≥4 despite loratadine and mometasone furoate nasal spray.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone furoate 50 mcg Rescue Treatment
Description: Mometasone furoate monohydrate nasal spray 50 mcg was dosed intranasally at a dose of one spray in each nostril once daily for participants aged 5 to \<12 years and a dose of 2 sprays in each nostril once daily for participants aged 12 to \<18 years as rescue medication for nasal symptoms of rhinoconjunctivitis among participants with a total symptom score of ≥4 despite loratadine and mometasone furoate nasal spray.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Albuterol 108 mcg Rescue Treatment
Description: Albuterol sulfate inhalation aerosol 108 mcg/inhalation was administered via inhalation at a dose of 2 inhalations every 4 to 6 hours as rescue medication among participants aged 5 to \<18 years with asthma symptoms .

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol 108 mcg Rescue Treatment
Description: Albuterol sulfate inhalation aerosol 108 mcg/inhalation was administered via inhalation at a dose of 2 inhalations every 4 to 6 hours as rescue medication among participants aged 5 to \<18 years with asthma symptoms .

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluticasone 44 mcg Rescue Treatment
Description: Fluticasone propionate inhalation aerosol 44 mcg/inhalation was administered via inhalation at a dose of 2 inhalations twice daily among participants aged 12 to \<18 years up to a maximum dose of 10 inhalations twice daily, in combination with albuterol, among participants with ≥4 albuterol sulfate inhalations/day for 2 days as rescue medication for nocturnal asthma or shortness of breath.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone 44 mcg Rescue Treatment
Description: Fluticasone propionate inhalation aerosol 44 mcg/inhalation was administered via inhalation at a dose of 2 inhalations twice daily among participants aged 12 to \<18 years up to a maximum dose of 10 inhalations twice daily, in combination with albuterol, among participants with ≥4 albuterol sulfate inhalations/day for 2 days as rescue medication for nocturnal asthma or shortness of breath.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone 5 mg Rescue Treatment
Description: Prednisone tablet 5 mg was administered orally at a dose of 1 mg/kg/day once daily up to a maximum of 50 mg/day on Day 1, and at a dose of 0.5 mg/kg/day once daily up to a maximum of 25 mg/day on Days 2, 3, 5, and 7 as rescue medication for asthma exacerbation at the discretion of the investigator.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone 5 mg Rescue Treatment
Description: Prednisone tablet 5 mg was administered orally at a dose of 1 mg/kg/day once daily up to a maximum of 50 mg/day on Day 1, and at a dose of 0.5 mg/kg/day once daily up to a maximum of 25 mg/day on Days 2, 3, 5, and 7 as rescue medication for asthma exacerbation at the discretion of the investigator.